Dopamine D 3 -preferring agonists are commonly used to treat Parkinson's disease and restless leg syndrome; however, laboratory animal studies suggest that they may possess a moderate abuse potential. These studies aimed to compare the highly selective, full D 3 agonist PF-592,379 to the less selective D 3 agonist 7-OH-DPAT, and the indirect dopamine agonist cocaine in drug selfadministration and discrimination assays. Although rats readily acquired high rates of fixed ratio (FR)1 responding for cocaine, experimentally naive rats failed to acquire responding when 7-OH-DPAT or PF-592,379 was made available during an 18-session acquisition period. Cocaine also maintained dose-dependent levels of responding when available under a FR5 or a progressive ratio (PR) schedule of reinforcement. Although 7-OH-DPAT maintained modest levels of responding when substituted under a FR5, it failed to maintain significant levels of PR responding. PF-592,379 maintained saline-like rates of responding when substituted under FR5 or PR schedules of reinforcement. Similar behavioral profiles were observed in cocaine discrimination assays, with 7-OH-DPAT partially substituting for cocaine, and PF-592,379 producing saline-like effects over a wide range of doses. Together, the results of these studies predict that highly selective D 3 agonists, such as PF-592,379, will have low abuse potential in humans.
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Introduction
The dopamine D 3 receptor has been hypothesized to play an important role in the reinforcing effects of drugs and other abuse-related behaviors (for reviews, see Newman et al., 2005; Heidbreder, 2008; Heidbreder and Newman, 2010) . Although normally expressed at low levels relative to D 2 receptors, D 3 receptors display a much more restricted, limbic pattern of distribution, with high levels of expression observed in brain regions considered to be important for reward, such as the nucleus accumbens (Sokoloff et al., 1990; Levesque et al., 1992; Gurevich and Joyce, 1999; Stanwood et al., 2000) . D 3 -preferring agonists, such as quinpirole, quinelorane, and 7-OH-DPAT, have been shown to produce a variety of cocaine-like effects in both monkeys and rats, including dose-dependent leftward shifts in the dose-response curve for cocaine self-administration (Caine and Koob, 1995; Caine et al., 1999 Caine et al., , 2000a , dose-dependent increases in cocaineappropriate responding in drug discrimination assays (Barrett and Appel, 1989; Katz and Witkin, 1992; Acri et al., 1995; Spealman, 1996; Baker et al., 1998; Sinnott et al., 1999; Caine et al., 2000b) , and the capacity to dose dependently maintain self-administration when substituted for cocaine (Caine and Koob, 1993; Nader and Mach, 1996; Sinnott et al., 1999; Collins and Woods, 2007) .
Although these effects suggest that the D 3 receptor may be involved in mediating the reinforcing effects of cocaine, D 3 -preferring and selective antagonists have generally failed to inhibit the ongoing self-administration of cocaine when the response requirements are low (Gal and Gyertyan, 2003; Xi et al., 2005; Xi et al., 2006; Xi and Gardner, 2007; Achat-Mendes et al., 2010) , raising the possibility that the activation of the D 3 receptor is not necessary for the reinforcing effects of cocaine.
Interestingly, the capacity of D 3 -preferring agonists to maintain self-administration appears to be dependent on the animal's prior experience with cocaine self-administration (Nader and Mach, 1996; Collins and Woods, 2007) , suggesting that their behavioral effects are altered following a history of cocaine administration. Consistent with these findings, experimenter-administered and selfadministered cocaine has been shown to result in an increase in the density/availability/expression of striatal D 3 receptors in both rats (Neisewander et al., 2004; Le Foll et al., 2005; Conrad et al., 2010; Collins et al., 2011) and humans (Staley and Mash, 1996; Segal et al., 1997) , as well as an enhancement in the D 3 -mediated behavioral effects of D 3 -preferring agonists in rats and monkeys (Hamilton et al., 2010; Collins et al., 2011) . Nevertheless, it is important to note that the D 3 -preferring agonist quinelorane failed to maintain responding when substituted for cocaine in mice with a genetic deletion (knockout) of the D 2 receptor (Caine et al., 2002) .
Although these findings suggest that the reinforcing effects of D 3 -preferring agonists are likely mediated by their actions at D 2 , rather than D 3 receptors, the relative contributions of the D 2 and D 3 receptors in the discriminative stimulus effects of cocaine are less clear. For instance, not only are D 2 -preferring and D 3 -preferring agonists equally effective at increasing cocaine-appropriate responding (Achat-Mendes et al., 2010) , but D 3preferring or selective antagonists and D 2 -preferring antagonists are equally effective at antagonizing the interoceptive effects of cocaine (Costanza et al., 2001; Martelle et al., 2007; Achat-Mendes et al., 2010) , suggesting that both receptor subtypes may play a role in mediating the discriminative stimulus properties of cocaine.
Although the development of antagonists that are B100fold selective for the D 3 over D 2 receptor in vitro (Reavill et al., 2000; Grundt et al., 2005) has allowed for significant advances toward understanding the role of the D 3 receptor in abuse-related behaviors, antagonists with a similarly high degree of selectivity for the D 2 receptor do not exist. Moreover, although agonists have been described with in-vitro radioligand-binding selectivities of B100-fold for the D 3 over D 2 (pramipexole; Millan et al., 2002) and B200-fold for the D 2 over the D 3 receptor (sumanirole; McCall et al., 2005) , neither of these compounds are capable of selectively activating the D 3 or the D 2 receptor over more than a 30-fold range of doses in vivo , making it difficult to parse the relative contributions of their D 3 and D 2 activities in self-administration and discrimination assays. Similar distinctions are commonly observed between the in-vitro selectivities obtained using radioligand binding and functional assays (Sautel et al., 1995) , suggesting that in-vitro functional selectivities may provide a more accurate predictor of in-vivo activity.
PF-592,379 is a novel agonist at the D 3 receptor that has been shown to possess a high degree of functional selectivity over both the D 2 (> 470-fold) and the D 4 (180-fold) dopamine receptor subtypes (Attkins et al., 2010) . The availability of this highly selective D 3 agonist provides an opportunity to compare its reinforcing and discriminative effects with a mildly D 3 -preferring agonist, 7-OH-DPAT, and with the indirect dopamine agonist, cocaine. First, we compared PF-592,379 with 7-OH-DPAT to determine its relative selectivity for the D 3 over the D 2 receptor in binding and functional assays. Next, we compared the acquisition of self-administration for PF-592,379, 7-OH-DPAT, and cocaine to assess its abuse potential in drug-naive rats. A dose-response analysis of the capacity of PF-592,379, 7-OH-DPAT, and cocaine to maintain responding under a fixed ratio (FR)5 and a progressive ratio (PR) schedule of reinforcement was also performed to allow for a comparison of each compound's relative reinforcing effectiveness. Finally, the capacities of PF-592,379 and 7-OH-DPAT to produce cocainelike interoceptive effects were evaluated in rats that were trained to discriminate cocaine from saline, and compared to the substitution profiles of the indirect dopamine agonist D-amphetamine and the k-opioid agonist U50,488.
Methods

In-vitro pharmacology
In-vitro binding assays
The binding affinities of PF-592,379 and 7-OH-DPATwere characterized at each of the five dopamine receptor subtypes using the following radioligands: [ 3 H]SCH23390 (D 1 and D 5 , 70 Ci mmol, 1 nmol/l), [ 3 H]U-86170 (D 2 , 62 Ci/mmol, 2 nmol/l), and [ 3 H]spiperone (D 3 and D 4 , 96 Ci/mmol, 0.2 nmol/l). CHO cells expressing recombinant human D 1 , D 2 , D 3 , D 4 , and D 5 receptors were rinsed with, and harvested in, ice-cold Ca 2 + /Mg 2 + -free phosphate-buffered saline before pelleting (500 g, 5 min), resuspension in 25 mmol/l Tris, 5 mmol/l EDTA, and 5 mmol/l EGTA, pH 7.5, and freezing the cells in liquid nitrogen. Upon thawing, the cells were homogenized and centrifuged at 1000g to remove nuclei and unbroken cells, with the supernatant subsequently centrifuged at 47 000g. The membrane pellet was then washed with Tris, EGTA, and EDTA, resuspended in 20 mmol/l HEPES, pH 7.5, 150 mmol/l NaCl, 10 mmol/l MgCl 2 , and 1 mmol/l EDTA, and frozen in liquid nitrogen before storage of membrane aliquots at -701C. Membranes were then thawed and diluted into 20 mmol/l HEPES, pH 7.4, 150 mmol/l NaCl, 10 mmol/l MgCl 2 , or 1 mmol/l EDTA, and 10 mmol/l MgSO 4 , with binding reactions carried out in a total volume of 0.9 ml for 1 h at room temperature, and stopped by vacuum filtration. Nonspecific binding was assessed with 3 mmol/l SCH23390 (D 1 -like antagonist) or 3 mmol/l haloperidol (D 2 -like antagonist). Competition binding experiments used 11 concentrations of PF-592,379 or 7-OH-DPAT run in duplicate. IC 50 values were determined by fitting the data to a one-site model by nonlinear leastsquares minimization, and K i values were calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) .
In-vitro functional assays cAMP accumulation was measured using a 24-well plate with intact CHO cells at a density of 15 000 cells/well using the same methods as Attkins et al. (2010) . Briefly, cells were plated 48 h before the experiment and incubated in serum-free medium 1 h before the experiment. Fresh medium (0.5 ml) containing 100 mmol/l forskolin, 100 mmol/l isobutyl methylxanthine, and varying concentrations of 7-OH-DPAT or PF-592,379 was then added to each well. cAMP accumulation was allowed to proceed for 15 min at room temperature, with termination of the reactions achieved by removing the medium and adding 100 ml of cold 7.5% trichloroacetic acid. Samples were diluted with 1.0 ml of 50 mmol/l sodium acetate, pH 6.2, and aliquots were assayed by radioimmunoassay using the Biomedical Technologies Incorporated (Stoughton, Massachusetts, USA) cAMP radioimmunoassay kit.
In-vivo pharmacology Subjects
Male Sprague-Dawley rats (280-330 g on arrival) were obtained from Charles River (Wilmington, Massachusetts, USA) and allowed to acclimate to the laboratory before experimentation. All rats were individually housed in plexiglas cages with kiln-dried pine shavings for bedding in a temperature (B221C)-controlled and humidity (B55%)-controlled environment under a 12-h light/dark cycle. Rats had free access to fresh tap water and standard fishmeal-based rat chow (Purina LabDiet 5001; PMI Nutrition International, Brentwood, Missouri, USA), with weights increasing to 350-500 g over the course of the studies. All procedures were performed in accordance with NIH Guide for the Care and Use of Laboratory Animals, and approved by the Institutional Animal Care and Use Committee.
Surgical preparation
To allow for the intravenous self-administration of drugs, a chronic indwelling silastic catheter was implanted under isoflurane anesthesia. Catheters consisted of a 13-cm long silastic tubing fitted to a 22-G guide cannula that was bent at a right angle, encased in dental cement, and anchored with a 0.5-in-diameter circular nylon mesh. The catheter was passed subcutaneously from the midscapular region and implanted into the right external jugular vein. Rats were allowed a recovery period of at least 7 days, with a prophylactic dose of ticarcillin (approximately 17 mg/kg; intravenously) dissolved in saline containing heparin (3 USP U/0.1 ml) delivered once daily for 5 days to prevent infection and maintain catheter patency. Thereafter, catheters were flushed daily with sterile physiological saline containing heparin (3 USP U/ 0.1 ml). Catheter patency was confirmed daily by checking whether blood could be drawn back from the catheter. If blood could not be drawn, catheter patency was assessed by administering a mixture of midazolam and ketamine (0.075/1.5 mg) sufficient to produce anesthesia within B3 s in animals with patent catheters. Animals with nonfunctional catheters were either implanted with a second catheter in the left external jugular or excluded from the study.
Apparatus
All self-administration studies were conducted in operant conditioning chambers (29.5 cm W Â 23.5 cm D Â 20 cm H), which were placed inside sound-attenuating cubicles equipped with a house light and an exhaust fan. Each chamber contained three response levers (ENV-110M; MED Associates Inc., Georgia, Vermont, USA), with two situated on the front wall of the chamber (3.0 cm above the grid floor and 1.5 cm from the side walls) and a third located at the center of the rear wall (3.0 cm above the grid floor). A single white stimulus light (ENV-221M; MED Associates Inc.) was located above each of the levers, and the illumination of the stimulus light above the active lever (center rear) served to signal that responding had scheduled consequences. A 3.3 rpm infusion pump (PHM-100; MED Associates Inc.) was mounted inside each chamber to allow for the intravenous delivery of drug or saline. Infusions were delivered through a single channel fluid swivel (Lomir Biomedical, Malone, New York, USA) that mounted on a balance arm and attached to a customized spring lead with an inner tygon tubing (Brian Fromant, Cambridge, UK). The other end of the swivel was connected through tygon tubing to a 10 ml syringe situated in the infusion pump to allow for the automated delivery of intravenous injections. Completion of the specified number of responses (i.e. the ratio) on the active lever resulted in the delivery of 1 U dose in a volume of 0.056 ml over 3.2 s. In conjunction with the start of the infusion, the session entered a 20-s timeout (TO) period, during which time the stimulus light was extinguished, and responding had no scheduled consequence. Following TO, the illumination of the stimulus light above the active lever signaled that responding once again had scheduled consequences.
Drug discrimination studies were performed in operant conditioning chambers that were identical to those described for self-administration studies, with the following exceptions: only two levers were present and the drug infusion equipment was replaced with a pellet dispenser (ENV-203M; MED Associates Inc.). Pellet dispensers delivered 45 mg sucrose pellets (A/I Rodent Pellets; P. J. Noyes Co., Lancaster, New Hampshire, USA) into a receptacle that was positioned in between the two levers and 2 cm above the floor. Stimulus lights above each of the levers served to signal that responding had scheduled consequences; however, they did not differentiate the active and the inactive levers.
Intravenous drug self-administration studies Acquisition studies
Three groups of seven drug-naive rats were used to compare the time course of the acquisition of responding for 0.32 mg/kg/injection (inj) of cocaine, 7-OH-DPAT, or PF-592,379. These doses of cocaine and 7-OH-DPAT were chosen on the basis of previous reports that they fall on the descending limbs of the dose-response curves in welltrained rats (Caine et al., 1999) . The dose of PF-592,379 was chosen on the basis of the results of pharmacokinetic studies, which suggest that a single intravenous dose of 0.32 mg/kg should produce estimated free drug plasma levels greater than the functional EC 50 of PF-592,379 at D3 receptors (Attkins et al., 2010) . Each chamber was equipped with three levers: one active and two inactive. Responses on the active lever resulted in drug infusions, and were reinforced under a FR1 TO 20-s schedule of reinforcement, whereas responses on either of the inactive levers were recorded, but had no scheduled consequence. Acquisition of responding was assessed over 18, 2-h sessions, conducted 5 days per week. The criteria for acquisition were defined as at least 15 injections per session and at least 70% of responding on the active lever over at least three consecutive sessions. These criteria were based on the rates of stable responding previously reported for rats maintained with 0.32 mg/kg/inj of either cocaine or 7-OH-DPAT (Caine et al., 1999) .
Upon completion of the acquisition studies, any rat that retained health parameters within specified criteria as well as a functional catheter was progressed to the FR and PR dose-response studies. Naive animals were added as necessary and trained to respond for cocaine under similar parameters until sufficient group sizes were obtained to evaluate 7-OH-DPAT and PF-592,379 in cocaine-trained rats.
Fixed-ratio dose-response studies
The capacities of cocaine, 7-OH-DPAT, and PF-592,379 to maintain responding were examined using rats (n = 6) that were trained to self-administer 1.0 mg/kg/inj cocaine under a FR5 TO 20-s schedule of reinforcement. Saline substitutions preceded the substitution of each dose of cocaine, 7-OH-DPAT, and PF-592,379 to allow the reinforcing effects of each dose to be evaluated from an extinction baseline (responding <50% of cocaine). Substitution sessions were initiated with a single noncontingent intravenous dose of the drug that would be available for self-administration, with each dose available for a minimum of two consecutive 2-h sessions, and there were no stability criteria in place during substitutions (i.e. rats were returned to 1.0 mg/kg/inj cocaine after two consecutive sessions had been completed). The order of cocaine (0.032-1.0 mg/kg/inj; intravenously), 7-OH-DPAT (0.032-1.0 mg/kg/inj; intravenously), and PF-592,379 (0.01-1.0 mg/kg/inj; intravenously) doses was determined by a Latin square design, with responding for 1.0 mg/kg/inj cocaine re-established and then extinguished (i.e. saline) before the substitution of each dose (from saline). All doses of a particular drug were evaluated in succession before the evaluation of the next drug. The different unit doses were delivered by adjusting the duration of the infusion so that a 0.032 mg/kg injection was delivered in B0.32 s, a 0.1 mg/kg injection was delivered in B1.0 s, a 0.32 mg/kg injection was delivered in B3.2 s, etc. with all infusion times adjusted for body weight. The initiation of the TO period always coincided with the start of the injection, and was held constant at 20 s regardless of the dose.
Progressive ratio dose-response studies Upon completion of the dose-response analysis under the FR5 schedule of reinforcement, cocaine, 7-OH-DAT, and PF-592,379 were also evaluated for their capacity to maintain responding under a PR schedule of reinforcement. Sessions were initiated with a single noncontingent intravenous dose of the drug that would be available for self-administration, and the response requirement was increased after each injection according to a logit function (3, 9, 13, 16, 18y) , with sessions terminating if a rat failed to complete a ratio within a 60-min period (i.e. 1-h limited hold), or after 6 h had elapsed, whichever occurred first. After the baseline criteria for the PR schedule were fulfilled (i.e. at least 10 injections of 1.0 mg/kg cocaine earned over two consecutive sessions with less than a 20% variation across sessions), saline was substituted for cocaine until responding occurred at less than 50% of that maintained by cocaine. Once the extinction criteria were fulfilled, the reinforcing effects of cocaine (0.032-1.0 mg/kg/inj; n = 4), 7-OH-DPAT (0.1-1.0 mg/kg/inj; n = 5), and PF-592,379 (0.1-1.0 mg/kg/inj; n = 4) were evaluated under the PR schedule of reinforcement. The order of drug and dose were determined by a Latin square design, with each dose available for at least two sessions, and separated by a redetermination of baseline responding for 1.0 mg/kg/inj cocaine and saline. The different unit doses were delivered by adjusting the infusion duration as described above; however, for PR studies the TO period only lasted as long as the infusion duration.
Drug discrimination studies Training procedures
Following initial shaping of lever responding, rats (n = 12) were trained to discriminate 5.6 mg/kg cocaine from saline using a two-lever discrimination task. On training days, rats received an intraperitoneal injection of either saline or 5.6 mg/kg cocaine, with the sequence of injections randomized, except for the following two restrictions: (a) the same injection could not be given for three consecutive sessions and (b) during each block of 30 training sessions, the numbers of saline and training drug sessions were approximately equal. Five minutes after the injection of saline or cocaine, a 25-min response period began. During this period, the house light and stimulus lights were illuminated and 20 food pellets were available under a FR schedule of reinforcement. The FR was gradually increased from a FR1 to a FR10. The positions of the saline-appropriate and cocaineappropriate levers were counterbalanced across rats, with ratio completion on the injection-appropriate lever resulting in the delivery of a single food pellet. Responses on the inappropriate lever reset the ratio requirement on the correct lever. If all 20 food pellets were earned before the end of the 25-min response period, the house light and stimulus lights were turned off and the session was terminated. Training sessions were conducted 5 days per week and continued until the following three criteria were fulfilled for seven of eight consecutive sessions: (a) at least 80% of responding during the first ratio occurred on the injection-appropriate lever; (b) at least 90% of the total session responding occurred on the injection-appropriate lever; and (3) all available food pellets were earned during saline training sessions.
Testing procedures
Once the training criteria were fulfilled, substitution tests began to evaluate the degree to which various drugs were able to produce responding on the cocaineappropriate lever. The contingencies that were in place for the test sessions were identical to those that were in place during training, with the exception that food was delivered following the completion of a FR10 on either lever. Completion of a ratio on either lever reset the ratio requirements for both levers. The drugs and doses that were tested were as follows: the indirect dopamine agonist cocaine (1.0, 3.2, 5.6, and 10.0 mg/kg; intraperitoneally), the D 3 -selective agonist PF-592,379 (0.32, 1.0, 3.2, 10.0, 18.0, and 32.0 mg/kg; subcutaneously), the D 3 -preferring agonist 7-OH-DPAT (0.1, 0.32, 0.56, 1.0, and 1.8 mg/kg; subcutaneously), the indirect dopamine agonist D-amphetamine (0.1, 0.32, 1.0, and 1.8 mg/kg; intraperitoneally) as a positive control, and the k-opioid agonist U50,488 (1.0, 3.2, and 10.0 mg/kg; intraperitoneally) as a negative control. The subcutaneous route was used for the D 3 agonists to facilitate the direct comparison of active doses between the discrimination assay (current studies) and the yawning assay (Collins et al., 2005 (Collins et al., , 2009 . Test sessions were separated by at least two training sessions, and were typically conducted twice per week. Substitution tests were conducted only if the performance during the intervening training sessions fulfilled the three criteria described above. If these criteria were not fulfilled, additional training sessions were run until responding once again fulfilled the criteria for stable discrimination.
Drugs
Cocaine HCl was supplied by NIDA/NIH, batch 11168-1022-43-3. 7-OH-DPAT [(±)-7-hydroxy-2-dipropylaminotetralin HBr; lot H8653-01K4028] and D-amphetamine sulfate (lot 074K1169) were purchased from Sigma (St Louis, Missouri, USA). PF-592,379 (5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine) was provided by Pfizer Inc. (Sandwich, UK; batch E010002137; 901/H/M/1). U50,488 (2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1ylcyclohexyl]acetamide) was obtained from Tocris Bioscience (Ellisville, Missouri, USA; batch 2A/79754). All doses reflect the salt form of the drugs. Sterile saline (0.9%) was used as a vehicle, with dose volumes of 1.0 ml/kg intraperitoneally or subcutaneously for discrimination studies. Infusion volumes varied as a function of dose for intravenous self-administration studies, with the 0.32 mg/kg/inj dose used in the acquisition studies delivered in a volume of 0.056ml over 3.2 s.
Data analysis
For self-administration studies, data are presented as the mean number of responses or injections ± SEM. For selfadministration studies in naive rats, the acquisition criteria were set at at least 15 injections per session and at least 70% of responding on the active lever over at least three consecutive sessions. For substitution studies under the FR5 and PR schedules of reinforcement, the maintenance of significant levels of responding (e.g. lever presses, injections earned, or final ratios achieved) was determined using one-way analysis of variance with repeated measures and Newman-Keuls post-hoc tests (GraphPad Prism; GraphPad Software Inc., San Diego, California, USA). For discrimination studies, the data are presented as the mean ± SEM percent of responding that occurred on the cocaine-appropriate lever and the mean ± SEM rate of responding (responses/s). The criterion for full substitution for the cocaine discriminative stimulus was at least 90% cocaine-appropriate responding.
Results
In-vitro experiments
The results of in-vitro binding and functional studies comparing PF-592,379 with 7-OH-DPAT are shown in Table 1 . In-vitro binding assays showed that PF-592,379 selectively bound D 3 receptors with a high affinity. Although PF-592,379 also bound to D 4 receptors, it displayed a 19-fold binding selectivity for D 3 over D 4 receptors. PF-592,379 failed to bind D 2 , D 1 , or D 5 receptors at concentrations of up to 10 mmol/l, and thus was at least 46-fold selective for D 3 over D 2 , D 1 , and D 5 receptors. Although 7-OH-DPAT bound to D 3 receptors with a higher affinity than PF-592,379, it failed to do so selectively as it was found to bind to the high-affinity site on D 2 receptors at similar concentrations. A similar distinction was observed in the inhibition of forskolinstimulated cAMP accumulation in CHO cells that stably expressed recombinant human D 3 or D 2 receptors. Not only did PF-592,379 function as a full agonist but it also displayed a 180-fold functional selectivity for D 3 over D 4 receptors. As was observed in binding studies, PF-592,379 did not show any functional activity at D 2 receptors, suggesting that it displays an in-vitro functional selectivity of at least 470-fold for the D 3 over D 2 receptors. 7-OH-DPAT displayed a much more limited in-vitro functional selectivity for the D 3 receptor over both the D 2 (two-fold) and the D 4 (35-fold) receptors.
Self-administration studies Acquisition studies in naive animals
As shown in Fig. 1 (left panels) , experimentally naive rats readily acquired responding when 0.32 mg/kg/inj cocaine was available under a FR1 schedule of reinforcement, with almost exclusive responding on the active lever observed by the end of the acquisition period. Although slight increases in active lever responding were observed when 7-OH-DPAT (0.32 mg/kg) was available for injection ( Fig. 1, center panels) , responding was much more variable from day to day, and rats generally failed to display a preference for the active versus inactive levers. Unlike with either cocaine, or 7-OH-DPAT, responding occurred at very low rates when 0.32 mg/kg/inj PF-592,379 was available for injection, with the average number of injections earned decreasing across the 18-day acquisition period. As shown in Table 2 , although a high percentage (five out of seven, or 71%) of rats acquired responding for cocaine, none of the experimentally naive rats acquired responding when lever presses resulted in injections of 7-OH-DPAT or PF-592,379. Although two of the seven rats that had access to 7-OH-DPAT fulfilled A D 3 -selective agonist lacks cocaine-like effects Collins et al. 285 the injection criterion by the end of the acquisition period, it is important to note that these relatively high levels of 7-OH-DPAT intake (Z 4.8 mg/kg) were accompanied by large increases in inactive lever responding and thus a low proportion of responding directed at the active lever.
Substitution studies in cocaine-trained animals
In addition to evaluating the acquisition of responding for 7-OH-DPAT and PF-592,379 in naive rats, a doseresponse analysis of the potential reinforcing effects of these compounds was also carried out in rats with a history of cocaine self-administration. As shown in Fig. 2  (top row) , when available under a FR5 schedule of reinforcement, cocaine maintained dose-dependent levels of responding [F(4,20) = 16.4; P < 0.001], with doses of 0.1 and 0.32 mg/kg/inj maintaining responding at rates that were significantly greater than those maintained by saline (P < 0.001 for both). Similarly, 7-OH-DPAT also maintained responding in a dose-dependent manner [F(2,24) = 5.0; P < 0.01]; however, responding was lower than that maintained by cocaine and only significantly greater than saline at the 0.1 mg/kg/inj dose (P < 0.05). Unlike with cocaine and 7-OH-DPAT, FR5 responding maintained by PF-592,379 remained low, and was no different than saline when cocaine-trained rats were provided access to a wide range of PF-592,379 doses.
As shown in Fig. 2 (bottom row) , a similar profile of responding was also observed when cocaine, 7-OH-DPAT, and PF-592,379 were available for responding under a PR schedule of reinforcement. Under this schedule, dosedependent [F(4,12) = 41.3; P < 0.001] and monotonic increases in responding were observed when ratio completion resulted in cocaine injections maintained, with doses of 0.1 (P < 0.01) and greater (P < 0.001) maintaining significantly more responding than saline. Although slight increases in responding were observed, 7-OH-DPAT failed to maintain PR responding at levels that were significantly different from saline. Low, salinelike levels of responding were observed when PF-592,379 was available for responding under a PR schedule of reinforcement. The average number of injections earned, responses emitted, and the final ratio achieved for the maximally effective dose of each drug and saline are summarized in Table 3 .
Drug discrimination studies
In addition to evaluating the capacity of PF-592,379 and 7-OH-DPAT to maintain responding in experimentally naive and cocaine-trained rats, these studies also assessed the degree to which they were able to substitute for the interoceptive effects of cocaine in rats trained to discriminate (5.6 mg/kg; intraperitoneally) cocaine from saline (Fig. 3) . Dose-dependent increases in cocaine-appropriate responding were observed following the intraperitoneal administration of either cocaine or D-amphetamine, with a full substitution (Z 90% cocaineappropriate responding) observed at doses of 3.2 and 1.0 mg/kg, respectively. Conversely, the k-opioid agonist U50,488 resulted in nearly exclusive responding on the saline-appropriate lever when administered at doses up to those that suppressed responding to B10% of baseline.
Although dose-dependent increases in cocaine-appropriate responding were observed with 7-OH-DPAT (maximum of 59% cocaine-appropriate responding), cocaine-appropriate responding failed to exceed 90% at doses up to those that suppressed responding to B10% of baseline. Unlike the intermediate levels of cocaine-appropriate responding that were observed with 7-OH-DPAT, nearly exclusive responding on the saline-appropriate lever (maximum of 3.5% cocaine-appropriate responding) was observed following the administration of PF-592,379 at doses up to those that suppressed responding to B15% of baseline.
Discussion
Dopamine D 3 -preferring agonists, such as 7-OH-DPAT and quinpirole, are known to maintain self-administration and dose dependently increase cocaine-appropriate responding in drug discrimination procedures in mice, rats, and nonhuman primates, suggesting that they possess an increased potential for abuse in humans. However, owing to the limited selectivity of these compounds for the D 3 over the D 2 receptors, it is unclear which of these receptor subtypes is responsible for the abuse-related effects. The current studies compared the effects of the D 3 -preferring agonist 7-OH-DPAT, and the novel D 3selective agonist PF-592,379, with those of the indirect dopamine agonist cocaine in rat self-administration and drug discrimination assays, with three main findings. First, unlike with cocaine, experimentally naive rats failed to acquire responding for either 7-OH-DPAT or PF-592,379 when injections were available under a FR1 schedule of reinforcement. Second, although 7-OH-DPAT maintained dose-dependent and significant levels of FR5 responding when it was substituted for cocaine, PF-592,379 failed to maintain responding that was any different from saline; neither maintained significant levels of responding under a PR schedule of reinforcement. Third, unlike 7-OH-DPAT, which produced a dosedependent, but partial substitution for the interoceptive effects of cocaine, PF-592,379 failed to increase cocaineappropriate responding when evaluated over a wide range of doses in the drug discrimination assay. When taken together, these findings not only support the notion that the abuse-related effects of D2-like agonists are mediated by their actions at the D 2 receptor, but they also provide the first evidence to suggest that highly D 3 -selective agonists would have a low abuse potential in humans.
In agreement with previous studies assessing the reinforcing effects of D2-like agonists in drug-naive rhesus monkeys (Nader and Mach, 1996) or rats (Collins and Woods, 2007) , both 7-OH-DPAT and PF-592,379 (0.32 mg/kg/inj) failed to support the acquisition of One-way, repeated-measures analysis of variance with Newman-Keuls post-hoc tests were used to determine doses that maintained significantly more responding than saline injections. FR, fixed ratio; Inj, injection; i.v., intravenously; PR, progressive ratio. responding when available to naive rats under a FR1 schedule of reinforcement, whereas responding was readily acquired when 0.32 mg/kg cocaine was available for injection. Although 7-OH-DPAT-maintained responding appeared to increase over time, a dose-related increase in inactive lever responding was also observed, suggesting that 7-OH-DPAT was unable to maintain responding in a schedule-appropriate and selective manner. In contrast, although PF-592,379-maintained responding occurred at moderate levels during the first 2 days of acquisition, responding decreased over time, with rats generally earning fewer than five injections per session by the end of the acquisition period. Although it is possible that rats may have acquired cocaine-like patterns of responding if larger unit doses of PF-592,379
(or lower unit doses of 7-OH-DPAT) had been evaluated, the doses available for acquisition were chosen on the basis of their position on the descending limb of a selfadministration dose-response curve (cocaine and 7-OH-DPAT, Caine and Koob, 1993; Collins and Woods, 2007) or their pharmacokinetic properties in rats (PF-592,379, Attkins et al., 2010) . With respect to PF-592,379, it is known to have good central nervous system penetration (cerebrospinal fluid to unbound plasma concentration ratio of 0.8-1.0; unpublished observation) and to produce pharmacologically relevant blood levels following a single intravenous dose of 0.1 mg/kg, with estimated free drug plasma levels B140 times greater than the EC 50 for PF-592,379 at D 3 receptors following a single intravenous dose of 2 mg/kg (Attkins et al., 2010) . Thus, in addition to being well within the range of Effects of the indirect dopamine agonists, cocaine and D-amphetamine, the k-opioid agonist U50,488 (left panels), and the D3 agonists 7-OH-DPAT (center panels) and PF-592,379 (right panels) in rats trained to discriminate 5.6 mg/kg cocaine from saline. The dose-response curves for each of the drugs on the percent of responding that occurred on the cocaine-appropriate lever are shown in the top row, whereas the effects of each of the drugs on the rates of responding are shown in the bottom row. Inj, injection; i.p., intraperitoneally; s.c., subcutaneously.
pharmacologically active doses, the fact that rats earned approximately 3 mg/kg of PF-592,379 during the first few acquisition sessions suggests that the inability of PF-592,379 to support the acquisition of responding did not result from an inactive dose of PF-592,379 being earned.
Despite the limitations of single-dose acquisition studies, differential patterns of responding emerged when 7-OH-DPAT and PF-592,379 were evaluated in rats trained to self-administer cocaine under FR5 or PR schedules of reinforcement. Consistent with previous reports in rats (Caine and Koob, 1993) , 7-OH-DPAT maintained dosedependent and significant levels of responding when injections were available under the FR5 schedule of reinforcement, suggesting that it effectively reinforced responding. Although consistent with previous reports in which cocaine self-administration has been shown to play an important role in establishing the response-maintaining effects of D 3 -preferring agonists in mice, rats, and monkeys (Nader and Mach, 1996; Caine et al., 2002; Collins and Woods, 2007) , 7-OH-DPAT failed to maintain significant levels of responding when substituted for cocaine under a PR schedule of reinforcement, suggesting that 7-OH-DPAT functions as a weak reinforcer relative to other drug reinforcers, such as cocaine. Unlike 7-OH-DPAT, low, saline-like rates of responding were observed when the D 3 -selective agonist PF-592,379 was substituted for cocaine under either a FR5 or a PR schedule of reinforcement, with rats earning fewer than five injections per session despite the fact that doses as large as 1.0 mg/kg were available for injection. This inability of PF-592,379 to maintain responding when evaluated over a wide range of doses, and under a variety of selfadministration paradigms, strongly suggests that the D 3 -selective agonist is devoid of any significant reinforcing properties in rats.
In addition to self-administration tests, drug discrimination procedures are commonly used in assessing a drug's abuse potential as they allow for the identification of pharmacologic mechanism(s) of action that may result in an increased risk for abuse in humans. Unlike the indirect dopamine agonists, cocaine and D-amphetamine, which produced a nearly exclusive selection of the cocaineappropriate lever, the D 3 -preferring agonist 7-OH-DPAT was only capable of producing B60% cocaine-appropriate responding when administered at a dose large enough to suppress responding. Although this partial effect is consistent with the partial to full substitution profiles commonly reported with other moderately D 3 -preferring agonists (B3-30-fold selective for D 3 over D 2 ), such as 7-OH-DPAT, PD-128,907, quinpirole, and pramipexole (Barrett and Appel, 1989; Witkin et al., 1991; Katz and Witkin, 1992; Terry et al., 1994; Acri et al., 1995; Filip and Przegalinski, 1997; Baker et al., 1998; Garner and Baker, 1999; Caine et al., 2000b) , it is important to note that substitution is typically observed at doses that are known to act at D 2 receptors in vivo (Collins et al., 2005 (Collins et al., , 2009 . Although both 7-OH-DPAT and PF-592,379 suppressed responding, large doses of 7-OH-DPAT also stimulated locomotor activity, an effect that is believed to be mediated by activation of the D 2 receptor (Millan et al., 2004) . Conversely, when administered at doses as large as 32.0 mg/kg, PF-592,379 produced only a mild inhibition of locomotor activity, suggesting that it lacked D 2 agonist activities. Thus, the inability of the D 3 -selective agonist PF-592,379 to substitute for the discriminative stimulus effects of cocaine not only distinguishes PF-592,379 from other D 2 -like agonists, but these findings also suggest that some degree of D 2 receptor activity is likely necessary for D 3 -preferring agonists to produce cocaine-like interoceptive effects in rats.
In addition to this unique behavioral profile of activity, in-vitro functional assays have also shown that PF-592,379 functions as a full agonist at the D 3 receptor with a functional selectivity of at least 470-fold for the D 3 over the D 2 receptor (Attkins et al., 2010) . This high degree of selectivity corresponds to PF-592,379 being at least 235 times more D 3 -selective than 7-OH-DPAT (current data) and at least 16 times more D 3 -selective than pramipexole (Blagg et al., 2007) , both of which have been shown to substitute for cocaine in drug self-administration and discrimination assays in rats (Caine and Koob, 1993; Acri et al., 1995; Filip and Przegalinski, 1997; Collins et al., 2012) . Given the high levels of predictive validity that are provided by these two assays (for recent reviews, see Carter and Griffiths, 2009; O'Connor et al., 2011) , the inability of PF-592,379 to maintain self-administration or substituted for the interoceptive effects of cocaine strongly suggests that highly selective D 3 agonists, such as PF-592,379, will have a low potential for abuse. This lack of abuse potential with PF-592,379 was also found in five clinical studies, carried out in healthy volunteers or patients with osteoarthritis, in which PF-592,379 failed to produce any adverse events suggestive of abuse potential. In contrast to the oxycodone comparator in two of the studies, PF-592,379 was not associated with any reports of euphoric mood, feeling drunk, or disorientation. Furthermore, in a study in which a cognitive test battery was used, PF-592,379 did not elicit any of the cognitive changes that are typically associated with drugs of abuse.
In summary, convergent lines of evidence were provided to suggest that the highly D 3 -selective agonist PF-592,379 does not possess cocaine-like reinforcing or subjective effects that may lead to an increased potential for abuse in humans. Furthermore, even though naive rats failed to acquire responding for either of the D 3 agonists, 7-OH-DPAT maintained FR5 responding in rats with a history of cocaine self-administration; PF-592,379 did not. Similarly, although the less selective D 3 agonist, 7-OH-DPAT, produced a dose-dependent substitution for discriminative stimulus effects of cocaine, PF-592,379 failed to do so, suggesting that it is devoid of cocaine-like interoceptive effects. Despite the similarities between the behavioral profiles of cocaine and 7-OH-DPAT, it is important to note that 7-OH-DPAT only partially substituted for cocaine in the discrimination assay, and failed to maintain responding when it was available for injection under a PR schedule of reinforcement, suggesting that the abuse potential of even moderately D 3 -preferring agonists is relatively low when compared with cocaine. Moreover, when taken together with the marked differences between the in-vitro functional selectivities of these ligands, the distinct behavioral profiles observed for 7-OH-DPAT and PF-592,379 strongly suggest that the attributes of D 3 -preferring agonists that may contribute to an increased abuse potential are mediated by their activities at the D 2 , rather than the D 3 receptors.
